Aims Amiodarone is the gold-standard medication to control heart rate in critically ill patients with atrial tachyarrhythmias (ATs); however, effective doses and covariates influencing its efficacy remain unknown. We therefore performed pharmacodynamic modeling of heart rate reduction induced by amiodarone in these patients.
Key Points
Amiodarone pretreatment, paroxysmal versus persistent atrial tachyarrhythmias (ATs), dobutamine infusion, intravenous magnesium and fluid loading have a significant influence on the effect of amiodarone on heart rate (HR) reduction in critically ill patients with AT.
An optimized dosing regimen of amiodarone that refines current guideline indications is proposed to better control HR in patients with AT depending on their clinical presentation: paroxysmal AT amiodarone-naive, persistent AT amiodarone-naive, and paroxysmal AT amiodarone pretreated.
Coadministration of intravenous magnesium with amiodarone is associated with a greater and earlier HR control in patients with AT. This suggests that systematic use of intravenous magnesium as an addon therapy might be valuable.
Introduction
Atrial tachyarrhythmias (ATs), such as atrial fibrillation, are highly prevalent and are associated with a poor outcome in critically ill patients admitted to intensive care units (ICUs) [1] . AT is often characterized by a persistent elevation of ventricular heart rate (HR) above 120-130 beats/min (bpm), leading to cardiac systolic dysfunction (i.e. ventricular tachycardiomyopathy), responsible for hemodynamic instability, and increased morbidity and mortality [2] [3] [4] [5] . A rate or rhythm control strategy with pharmacological therapy is recommended in patients with AT for the treatment or prevention of ventricular tachycardiomyopathy [4, 5] . Before initiating antiarrhythmic treatment, factors promoting AT in the critically ill should be sought and corrected (anemia, hypoxia, hypokalemia, etc.). Anticoagulant treatments are also usually administered. Attempts to restore sinus rhythm are frequently unsuccessful in the setting of critically ill patients [6] [7] [8] , particularly when using electrical cardioversion (ECV) without antiarrhythmic pretreatment. Thus, HR control is the main preferred strategy in this situation [9] [10] [11] . Guidelines in stable patients recommend strict control aimed at a resting HR of between 60 and 80 bpm, and 90 and 115 bpm during stress situations, based on the results of the AFFIRM trial [4, 12] . No specific guidelines are available for severely ill patients, but it is commonly admitted that reaching an HR below 115 bpm is advisable [2] [3] [4] [5] .
Amiodarone is the recommended agent for controlling HR in critically ill patients presenting with AT [4, 5] ; however, it can be associated with hypotension and potentially severe liver and pulmonary toxicity, particularly after intravenous administration [4, [13] [14] [15] . This toxic risk justifies the administration of the lowest possible dose to control HR. In addition, patients admitted to the ICU present with a diversity of adverse conditions that can affect antiarrhythmic drug pharmacokinetics and dynamics, including unstable hemodynamics, pre-existent or acquired left ventricular dysfunction, hypoxemia, hyperthermia, hypovolemia, or acidosis [16] .
The choice of amiodarone doses in ICU patients is thus challenging due to interpatient heterogeneity and limited knowledge of optimal dosing in this setting [4, 5] . In general, an intravenous loading dose of 300 mg is administered over 1 h, followed by an additional dose administered either intravenously over the first day (10-50 mg/h) [10] or orally over the next few days (400 mg/day, up to 1200 mg/day) [4, 5, 17, 18] . In daily practice, amiodarone dosing regimens used in these patients vary widely. Factors that influence amiodarone efficacy in critically ill patients have not been reported; therefore, a randomized study comparing the efficacy of different amiodarone dosing regimens would be inappropriate without previous knowledge of the sources of variability of drug response in ICU patients. Modeling of amiodarone efficacy in critically ill patients has not been previously reported and is the best initial approach to better characterize the complex interactions of multiple covariates on the pharmacodynamics of amiodarone.
The objective of this study was to determine optimal doses of amiodarone to achieve an HR of between 80 and 115 bpm when treating AT after identification and integration of clinical and therapeutic covariates influencing amiodarone efficacy in critically ill patients.
Materials and Methods

Patients and Study Design
This observational, cohort study was conducted from January 2007 to April 2012 in the 18-bed medical ICU of a tertiary teaching hospital. Due to the observational design, and in accordance with French bioethics laws, Institutional Review Board authorization was not necessary. In this study, the use of computerized medical data with protection of patient confidentiality was approved by the Commission Nationale de l'Informatique et des Libertés. Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU. Three investigators (J-ES, ME-A, MA) were each responsible for data extraction during a specified time period, resulting in the inclusion of patients over three distinct time periods (Fig. 1) . Patients with paced rhythm or incomplete charts were excluded. HR data were collected at the moment of the first amiodarone administration in the ICU, and then four to six times daily after each dosing over 6 days, or until death or ICU discharge. Amiodarone could be administered either intravenously over 20-60 min, or orally. Route, frequency of administration, and doses were prescribed at the discretion of the treating physician, without any predefined protocol.
Variables
At the time of first amiodarone administration in the ICU, the following time-independent covariates were collected: sex, age, body weight, height, etiology of the disease leading to ICU admission, Simplified Acute Physiology Score II (SAPS II), Acute Physiology And Chronic Health Evaluation II (APACHE II) score, diabetes, hypertension, past medical history of AT, withdrawal of a chronic antiarrhythmic drug since less than three times its half-life, total bilirubinemia, previous amiodarone treatment before first dose in the ICU (yes, no), type of cardiac rhythm (sinus vs. persistent/paroxysmal AT). Paroxysmal and persistent AT were defined as an arrhythmia that started less than or more than 1 week before the first amiodarone administration in the ICU, respectively.
Time-dependent covariates potentially interacting with amiodarone pharmacokinetics and/or pharmacodynamics were also collected at the time of each HR collection, i.e. temperature, pH, pa02, natremia, kalemia, hemoglobin, protidemia, glomerular filtration rate, attempt to ECV, magnesium or fluid loading, use of other antiarrhythmic drugs, furosemide or extrarenal dialysis with or without ultrafiltration, catecholamine administration and its type (epinephrine \1 mg/h, epinephrine [1 mg/h, dobutamine, other b-adrenoceptor agonists), curare, and sedative drug use. Fluid loading was defined as administration of more than 0.5 L of saline solution in 30 min, and magnesium loading was defined as any administration of intravenous magnesium either by bolus or continuous infusion, whichever the dose received. Influence of other antiarrhythmic drugs could not be analyzed because such prescription was too rare to be studied.
Pharmacodynamic Modeling
General Model
Amiodarone pharmacokinetics were ascribed to a virtual compartment model including zero or first-order input rates. This virtual compartment [A(t)] represents the biophase in which the amount or concentration is in equilibrium with the observed effect. It is used to extract the kinetic component [KDE or 'pharmacodynamic half-life'] from the pharmacodynamic data alone describing the equilibrium between the administration rate and the observed effect. G(t) represents the amiodarone amount in the gut at a given time, and ka represents the first-order absorption rate (fixed to 8) [19] [20] [21] . Amiodarone bioavailability (F) was fixed to 0.33 [19] [20] [21] . The effect of amiodarone on HR [HR(t)] was modeled as follows:
In the effect model (Eq. 4), the production rate constant of response HR (k in ) is inhibited by the amiodarone virtual infusion rate (IR; drug amount per time unit) via an hyperbolic function. Finally, IR 50 and k out are the IR that induces 50 % of the maximal response and the first-order dissipation rate constant for the HR response. It was shown that the use of the IR function usually performs well and can be used for predictions of drug effects [26] , provided the investigated doses extend well beyond the IR 50 , which is the case in this study ( Table 1) .
The initial conditions of these differential equations were HR 0 = HR at time zero, A 0 = dose for intravenous administration, and G 0 = F 9 dose for oral route. 
Influence of Covariates
Several time-dependent variables were tested and were included in the response model when they significantly [percent relative standard error (%RSE) \50 %] modified either k in (ModK in ) or k out (ModK out ) as follows:
where MG, DOBU, FILL, and ECV denote magnesium loading, b-agonist administration, fluid therapy, and ECV (only when effectively restoring sinus rhythm), respectively, with their corresponding t SUBSCRIPT influential parameters.
where FRetro HR denotes the parameter modulating the importance of spontaneous retrocontrol to a reference value (HR REF ), depending on the type of cardiac rhythm at the time of first amiodarone administration in the ICU.
Several time-independent factors were tested and were included in the response model when they significantly (% RSE \50 %) modified either baseline HR before the first amiodarone dose in the ICU (HR 0 ), or k out or HR REF Covariate effects on structural parameters were only tested and included if they were physiologically plausible. For example HR 0 is known to be faster in patients with AT compared with patients in sinus rhythm, therefore this covariate effect can be accepted if it is significant.
The inclusion of patients in sinus rhythm was useful because they received the lowest amiodarone doses, and thus served to validate the model over a large dose range. These subject specificities were very well-identified during the modeling process since the 'sinus rhythm' covariate had a significant effect on the three major elements of our model: HR 0 (i.e. baseline HR at the time of amiodarone administration), K out , and Reference HR. 3 Results
Patients and Observations
Among the 856 consecutively screened patients admitted to the ICU, 97 (11.3 %) had received at least one amiodarone dose for AT. Seventeen patients had paced rhythm or incomplete chart data and were therefore excluded, leaving 80 patients eligible for analysis ( Fig. 1) . In these 80 patients, 1348 time-HR observations with 361 amiodarone dose administrations were available during a maximum of 6 days after the first dosing in the ICU. In our dataset during the observed period, patients with paroxysmal AT (n = 47) had an HR above 115 bpm less frequently than APACHEII Acute Physiology And Chronic Health Evaluation at ICU admission, ICU intensive care unit, SAPS II Simplified Acute Physiology Score at intensive care unit admission, TSH thyroid-stimulating hormone a TSH was available in 35 subjects within 10 days before first administration of amiodarone in the ICU. Among these patients, none had a TSH below the lower normal limit (\0.2 mUi/L) and three had a TSH above the upper normal limit ([5.2 mUi/L) patients with persistent AT (n = 25): 37 % (261/706) versus 47.7 % (224/470) of HR collected (p = 0.02), respectively. Among patients initially diagnosed with AT in our dataset (n = 72), 33 (46 %) never returned to sinus rhythm, while 39 had at least one ECG in sinus rhythm. Among those latter 39 patients, AT relapsed in 12 patients. Overall, sinus rhythm was restored in only 14 patients (19 %) within 24 h of the first amiodarone administration in the ICU, without recurrence of AT. ECV was delivered to nine patients, and was successful in only four patients, two of whom were successful after several attempts at distinct times of care. These data confirm the difficulty in achieving and maintaining HR control or sinus rhythm in clinical practice. More details about HR data collection and amiodarone doses are summarized in Table 1 . Patients were severely ill, had cardiovascular comorbidities, and received amiodarone during their ICU stay mainly for poorly tolerated paroxysmal atrial fibrillation. Dobutamine (10 %) or epinephrine (56 %) were the only intravenous catecholamines used. Before first amiodarone administration in the ICU, 52 patients were naive of amiodarone pretreatment (74 % patients with paroxysmal AT and 26 % with persistent AT), and 28 patients had previously received amiodarone. Thirty patients (37.5 %) received magnesium loading as add-on therapy on top of amiodarone to control HR, and only two patients received digoxin. The main clinical, demographic, and biological patient characteristics are summarized in Table 2 . Patients were mainly admitted for cardiogenic shock or sepsis. No stroke was identified during the patients' stay in the ICU. Other treatments received by the patients that could interfere with HR control are summarized in Table 2 .
Impact of Amiodarone Pretreatment and Type of Atrial Tachyarrhythmias on Amiodarone Doses Needed to Control Heart Rate
Baseline HR before the first administration of amiodarone in the ICU (defined as HR 0 ) was higher (Table 3) in amiodarone-naive patients with paroxysmal AT than in amiodarone-pretreated patients with paroxysmal AT or amiodarone-naive patients with persistent AT (154 ± 4 vs. 132 ± 35 and 131 ± 6 bpm, respectively; p \ 0.0001). We modeled the effect of different amiodarone dosing regimens on HR reductions in these three different clinical scenarios and took the optimal dosing regimen to achieve an HR of 90 bpm as an example (Fig. 3 ). The amiodarone doses were then extrapolated from these simulations results. AT atrial fibrillation, Amio 50 amiodarone dose that induces 50 % of putative maximal effect on HR reduction, DOBU b-agonist administration, bpm beats/min, BSV between-subject variability, ECV electrical cardioversion, FILL fluid therapy, FRetro HR factor determining the importance of endogenous spontaneous retrocontrol of the HR to a reference HR depending on the type of cardiac rhythm at the time of first administration of amiodarone in the ICU, HR 0 heart rate at t 0 before first amiodarone administration in the ICU, ICU intensive care unit, KDE rate constant describing the equilibrium between the administration rate and the observed effect, k out first-order constant rate for amiodarone effect kinetics, % RSE percent relative standard error, NA not applicable, MG magnesium loading, Parox paroxysmal atrial tachyarrhythmia that started less than 1 week before the first amiodarone administration in the ICU, Reference HR estimated heart rate that the subject tended to reach spontaneously by endogenous retrocontrol, 9 indicates multiplication Among patients with paroxysmal AT, slightly higher doses of amiodarone were needed to achieve an HR below 115 bpm within the first day and to maintain it around 90 bpm for the 4 subsequent days in amiodarone-naive patients compared with amiodarone-pretreated patients (due to the difference in baseline HR; Fig. 3a, b) . In silico simulations indicated that the amiodarone dosing regimen to achieve such HR control in amiodarone-naive patients with paroxysmal AT should be a 300 mg intravenous loading dose on day 1 plus an 800 mg oral dose from days 1 to 5 (Fig. 3a) . Corresponding doses indicated by the model were slightly lower in patients with paroxysmal AT pretreated with amiodarone: a 300 mg intravenous loading dose on day 1 plus a 400 mg oral dose from days 1 to 5 (Fig. 3b) .
Interestingly, despite a lower baseline HR in amiodarone-naive patients with persistent AT, corresponding doses were almost twice those of amiodarone-naive patients with paroxysmal AT (600 mg intravenous loading dose on day 1, and 1400 mg oral doses from days 1 to 5) (Fig. 3c) . This relative resistance of persistent AT was associated with a decrease in the amiodarone effect (k out ) in patients with persistent AT compared with paroxysmal AT (Table 3) .
Impact of Dobutamine Infusion, Electrical Cardioversion, Magnesium and Fluid Loading on the Effect of Amiodarone
We then assessed the effect of covariates on the effect of amiodarone. Among the covariates analyzed, ECV (p \ 0.05), dobutamine infusion (p \ 0.05), intravenous magnesium (p \ 0.02), and fluid loading (p \ 0.02) had a significant positive impact on amiodarone pharmacodynamics in ICU patients with AT. Use of furosemide, extra-renal dialysis, epinephrine infusion, curare, and sedative drugs had no significant impact. Underlying pathologies, hemodynamic conditions, kidney function, and baseline clinicobiological values (Table 2 ) also had no significant impact. Figure 3d -f show that the use of magnesium and/or fluid loading on the first day were associated with a greater and earlier HR decrease than that suggested by the pharmacodynamic half-life of amiodarone (3.33 ± 0.9 days) ( Table 3 ). In contrast, the efficacy of amiodarone on HR control decreased if dobutamine was used ( Fig. 3d-f ).
Discussion
The present study indicates that amiodarone doses needed to control HR should be almost twice as high in persistent AT compared with paroxysmal AT [4, 19, 22] . Patients who had received amiodarone before their first ICU administration required lower doses. Our pharmacodynamic model also showed that the main interventional covariates influencing amiodarone efficacy were dobutamine use, ECV, and magnesium and fluid loading.
A Mixed Oral and Intravenous Loading Dose Over a Few Days
Due to incomplete bioavailability and delayed oral absorption [19] [20] [21] , a 300 mg intravenous loading dose is recommended [4, 5] to rapidly achieve the aimed HR. Thus, the total daily dose that may be administered safely is expected to be higher with the oral route, avoiding hypotension, hemodynamic impairment and phlebitis, which can specifically occur with intravenous amiodarone infusion [4, [23] [24] [25] [26] . An oral loading dose regimen up to 30-50 mg/kg over 5 days [27] was proven to be safe and effective. In our model, we therefore chose to test a rapid and safe therapeutic strategy combining an intravenous and oral dosing regimen over 5 days. According to our model, the different proposed dose scheme (a 300-600 mg intravenous loading dose on day 1 plus a 400-1400 mg oral dose from days 1 to 5) in patients with paroxysmal or persistent AT, amiodarone-pretreated or not, agrees with b Fig. 3 Model-predicted effect of amiodarone on HR in bpm. Shown are the effects in case of paroxysmal ATs in amiodarone-naive patients before first administration in the ICU (a, d; baseline HR 154 bpm); paroxysmal AT in patients pretreated with amiodarone (b, e; baseline HR 132 bpm); and persistent AT in amiodarone-naive patients (c, f; baseline HR 131 bpm). a-c Representation of the evolution of HR over 5 days following several doses of amiodarone. Shown are the effects of a 300 mg intravenous loading dose on D1 combined with a 200/400/600/800/1200 mg (purple, green, light blue, dark blue and black line, respectively) oral dose on the first day followed by an equivalent oral dose for 4 days (D1-5). The orange line represents the effect of a 600 mg intravenous loading dose on D1 combined with a 1400 mg oral dose on the first day followed by an equivalent oral dose for 4 days (D1-5). Compared with the case of an amiodarone-naive patient with paroxysmal AT (a), doses needed to achieve an HR of between 80 and 115 bpm are lower in patients with paroxysmal AT pretreated with amiodarone (b), and higher in amiodarone-naive patients with persistent AT amiodarone (c). In a, b, and c, the bold line represents the proposed dose scheme to use in clinical practice according to the situation (300/300/600 mg intravenous loading dose plus 800/400/1400 oral dose, respectively). This latter dose scheme (a-c) is used in d, e, and f, respectively, for further evaluation. d-f Representation of the evolution of HR over the first day following a selected amiodarone dose alone (continuous lines) or in case of concomitant dobutamine use (plus-symbol lines), fluid therapy over 12 h (dotted lines), and/or magnesium loading over 24 h: for Mg alone (dashed lines), or for combined Mg and Fill (dashdotted lines). Use of magnesium and/or fluid loading on the first day, as add-on therapy with amiodarone, was associated with a faster and greater HR decrease. Efficacy of amiodarone on HR control decreased in case of persistent AT or if dobutamine was used. bpm beats per minute, HR heart rate, AT atrial tachyarrhythmia, ICU intensive care unit, D1 day 1, Amio amiodarone, DOBU dobutamine, Fill fluid therapy, Mg magnesium the recommended doses [4, 5, 18, 27] but provides a more specific approach in each group. Pharmacologic cardioversion with amiodarone is not effective in the short and medium term. At 24 h, amiodarone has inconsistently demonstrated increased restoration of sinus rhythm when compared with placebo in some, but not all, randomized studies [4, 5] . We therefore focused on HR reduction, which is a clinically relevant therapeutic endpoint in critically ill patients [4, 5, 10] .
Amiodarone Pharmacodynamics in the Intensive Care Unit
We identified four interventions that influenced amiodarone efficacy in critically ill patients with AT. Dobutamine use was associated with decreased amiodarone efficacy, while ECV and fluid and magnesium loading were associated with earlier and better HR control. Fluid therapy, defined as infusion of more than 0.5 L of saline administered over 30 min, was administered to patients with apparent or real hypovolemia, and was significantly associated with better HR control. By correcting hypovolemia, reflex tachycardia may have decreased [28] . Dobutamine is a b-adrenergic agonist leading to tachycardia and supraventricular arrhythmias [29] to a greater extent than other catecholamines, such as epinephrine [30] . In our model, dobutamine significantly influenced the pharmacodynamics of amiodarone, while this interaction was not found with epinephrine. Interestingly, intravenous magnesium, which is recommended to prevent postoperative AT [4, 31] , was found to improve HR control of patients with AT treated with amiodarone. Further investigations are required to confirm the present findings before extrapolating our results to other patient populations and procedures for the treatment of AT. ECV was rarely used or was rarely efficient to restore sinus rhythm in our patients. Ineffective or immediate recurrence of AT after ECV is an important concern in critically ill patients, and even more so when AT is persistent [4] . ECV success rates as low as 30 % are reported in these patients [32, 33] . Impregnation with antiarrhythmic drugs such as amiodarone increases the probability of restoring and maintaining sinus rhythm [4, 34, 35] .
No significant influence of the etiology of shock, sedative, and curare drugs on amiodarone efficacy was observed. Neither furosemide administration nor ultrafiltration were identified as significant covariates. We hypothesized that patients treated with these depletive strategies had high pretherapeutic filling pressures and did not experience hypovolemia and reactional HR increase [28] . The type of AT was not a significant covariate but caution is needed because patients included in this modeling were mostly patients with atrial fibrillation and few data were available for other types of arrhythmia such as atrial flutter. Amiodarone and its metabolite N-desethylamiodarone are eliminated by hepatic route, and marginally eliminated by the kidney. In patients receiving hemodialysis or intermittent peritoneal dialysis, amiodarone and its metabolite were not found in the dialysate [36] . In the present study, we did not find any influence of creatinine clearance or extrarenal dialysis on the model parameters. b-blockers and verapamil were used exceptionally in this study because of their negative inotropic effects. Digoxin was also very rarely used because of its poor efficacy to rapidly slow HR and significant interaction with amiodarone that may lead to adverse events [4, 5] .
Limitations
In this observational study, we did not take into consideration other unavailable covariates of interest that may influence drug response. However, this study provides for the first time the basis for designing a future prospective trial of amiodarone dosing in ICU patients with AT. In addition, the therapeutic strategy based on our model should now be prospectively tested to compare whether a tailored amiodarone dosing strategy according to the duration of AT (paroxysmal vs. persistent) and other significant covariates (amiodarone pretreatment or not, coadministration of magnesium or not, on/off dobutamine) is more efficient and more convenient (less bradycardia and hypotension issues) for achieving an optimal HR control than a lenient strategy relying on physician's decisions without any standardized protocol.
Left atrial volume is inversely correlated to the amiodarone dose needed to restore or maintain sinus rhythm after AT [37] . To date, the influence of left atrial volume on the ability of amiodarone to control HR is still unclear [18, 22, 38, 39] . The impact of the size of the left atrial could not be tested in our model due to incomplete data in too many patients.
Plasma levels of amiodarone and its metabolite N-desethylamiodarone were not tested in our model because amiodarone therapeutic drug monitoring is not recommended [4, 5] in clinical practice. It is theoretically conceivable that including plasma concentrations of amiodarone and N-desethylamiodarone could have improved our predictions; however, this is unlikely since individual plasma concentrations are poorly predictive of pharmacodynamic response [40, 41] .
Our patients with paroxysmal AT pretreated with amiodarone had very heterogeneous doses before first administration in the ICU. Due to our observational design, these pre-admission doses could not be precisely identified. In our model, we found that this covariate significantly influenced baseline HR. Baseline HR in this subgroup of patients was quite scattered (132 ± 35 bpm) compared with other subgroups, and was lower than in amiodaronenaïve patients with paroxysmal AT (154 ± 3 bpm). This difference in baseline HR between these latter groups could be explained by the fact that patients pretreated with amiodarone were already under its slowing effect on HR. Thus, our recommended doses of amiodarone for this subgroup of amiodarone-pretreated patients with paroxysmal AT was the lowest proposed and will be applicable only if baseline HR is in the 130-135 bpm range. Even lower doses would be needed if this baseline HR is lower than 120 bpm, and higher doses would be needed in patients with baseline HR above 140 bpm.
Perspectives
This work, modeling amiodarone efficacy to control HR in critically ill patients with AT, identified several clinically relevant covariates that influenced its pharmacodynamics. Taking into account these covariates might achieve better individualization of amiodarone dosing for poorly tolerated AT in critically ill patients. Compared with paroxysmal AT, double doses are needed in persistent AT. Before ICU admission, amiodarone-pretreated patients needed lower doses than amiodarone-naive patients. Correction of hypovolemia, magnesium administration, and use of lower dobutamine doses also contributed to better control of HR.
This study suggests that coadministration of magnesium with amiodarone is associated with greater and earlier HR control in critically ill patients with AT. Lower amiodarone doses might be needed to slow AT in case of coadministration of magnesium, thereby potentially lowering the incidence of amiodarone adverse events. Administration of high doses of magnesium versus placebo as an adjunct to ibutilide to treat AT, a class III agent, was associated with a higher conversion rate to sinus rhythm and less ventricular arrhythmia [42] . To date, prophylactic use of intravenous magnesium has been shown to reduce the probability of postoperative AT [31] , but data regarding its efficacy in acute constituted AT remain scarce, particularly when combined with amiodarone. We are planning to further investigate this issue by conducting a prospective study evaluating intravenous magnesium as add-on therapy to amiodarone in order to treat AT in critically ill patients.
Conclusions
In critically ill patients with AT, our results indicate that doses of amiodarone needed to control HR are higher in persistent AT than in paroxysmal AT. In contrast, patients who had received amiodarone before their first ICU administration required lower doses. In critically ill patients, optimization of fluid therapy, decreasing dobutamine infusion as soon as possible, and magnesium supplementation may also help control HR in AT.
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